PressSeptember 7, 2023 Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to Supply Special Access Program
PressSeptember 6, 2023 Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial Of AWKN-P001
PressSeptember 6, 2023 Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
PressSeptember 6, 2023 American Psychedelic Practitioners Association Retains The Daschle Group as Government Affairs Counsel
PressSeptember 6, 2023 COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
PressSeptember 6, 2023 PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
PressSeptember 6, 2023 Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
PressSeptember 5, 2023 Origin Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
PressSeptember 5, 2023 BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
PressSeptember 5, 2023 Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing
PressSeptember 5, 2023 MindBio Therapeutics Corp. Announces Major Genetic Discovery in Microdosing Research
PressSeptember 1, 2023 California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments
PressAugust 31, 2023 MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
PressAugust 29, 2023 PSYC Enters Strategic Partnership with Target Media to Help Accelerate Audience and Revenue Growth Opportunities
